Skip to content

In-vivo Bioequivalence Study of Metformin 500 mg FC. Tablets of The Test Drug ( Sajjad Darou, Iran)

In-vivo Bioequivalence Study of Metformin 500 mg FC. Tablets of The Test Drug ( Sajjad Darou, Iran) in Compared with The Reference Drug (GLUCOPHAGE® 500 mg. Merck Serono, Germany) In Iranian Healthy Volunteers

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200105046010N106
Enrollment
24
Registered
2024-06-22
Start date
2024-08-05
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

This study is performed on healthy volunteers and drug concentration in plasma is determined..

Interventions

Intervention 1: Intervention group: single dose, one oral tablet GLUCOPHAGE® 500 mg as a reference product. after washout period, the volunteers receive Metformin 500 mg tablet manufactured by Sajja

Sponsors

Sajad darou shargh
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: General Health (Liver, Heart, and Kidney) Body Mass Index (18-28) kg/m^2 Age (18-55 years old) Informed consent

Exclusion criteria

Exclusion criteria: Nicotine consumption history Cardiovascular disease History Liver and kidney Alcohol and opioid addiction Allergy reactions history to metformin

Design outcomes

Primary

MeasureTime frame
Drug plasma concentration. Timepoint: 0.5? 1? 1.5? 2? 2.5? 3? 3.5? 4? 4.5? 5? 6? 8? 10,12, 24 h after drug administration. Method of measurement: Liquid Chromatography Mass-Mass.

Secondary

MeasureTime frame
Time to reach maximum plasma concentration. Timepoint: After intervention. Method of measurement: Time to reach the maximum drug concentration in plasma is recorded.;Extent of absorption. Timepoint: After intervention. Method of measurement: Calculation of area under curve of concentration -time.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactJavad Shokri

Tabriz University of Medical Sciences

shokri.j@gmail.com+98 41 3661 4125

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026